KOL Perspectives on BTK Inhibitors in RA, 2018 Study - ResearchAndMarkets.com

DUBLIN--()--The "KOL Perspectives: BTK Inhibitors in RA" drug pipelines has been added to ResearchAndMarkets.com's offering.

This KOL Insight briefing focuses on KOLs views of BTK Inhibitors in RA.

Questions topics

  • Awareness and potential of BTK inhibitors in RA
  • Perceptions of BMS-986142's Phase IItrial design
  • Impact of poseltinib discontinuation on existing perception of BTK inhibitors in RA

Key Highlights

  • Of the named BTK inhibitors, KOLs demonstrated the greatest awareness of BMS-986142, despite its lack of Phase II data
  • KOLs were divided over BMS-986142's ability to achieve ACR70 by Week 12 in a refractory patient population
  • For the majority of KOLs, poseltinib's discontinuation had little to no impact on their existing perception of BTK inhibitors in RA.

Scope

  • The insight briefing is based on Sociable Pharma's analysis of primary research with our RA key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs -

  • 5 Europe-based & 5 N. America-based
  • Interviews performed during Q2 2018

KOL data is analyzed to produce -

  • Charts summarizing KOL opinions
  • Chart call-outs of key information & details
  • KOL quotes
  • Summary of KOL reporting trends
  • Insight from Sociable Pharma's analysts

Reasons to Buy

  • Combines Qualitative & semi-quantitative insight from key opinion leaders on BTK Inhibitors in RA
  • Includes insight & recommendations from our disease-specific healthcare analysts
  • Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of RA
  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Key Topics Covered:

  1. Executive Summary
  2. Background
  3. Research Panel Composition
  4. Results & Implications
  5. Appendix

Companies Mentioned

  • BMS
  • Lilly
  • Roche
  • Merck
  • AbbVie

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/nwftwp/kol_perspectives?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs